Neuroleptics modulate cytokine and reactive oxygen species production in blood leukocytes of healthy volunteers

Archivum Immunologiae et Therapiae Experimentalis

Volumn 52, Issue 1, 2004, Pages 59-67

  Szuster Ciesielska, Agnieszka ^a   Słotwińska, Maria ^a   Stachura, Anna ^a   Marmurowska Michałowska, Halina ^b   Kandefer Szerszeń, Martyna ^a  

^a MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Chlorpromazine; Clozapine; Cytokines; Haloperidol; Neutrophils; Peripheral blood mononuclear cells; Reactive oxygen species

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; CYTOKINE; GAMMA INTERFERON; HALOPERIDOL; HYDROGEN PEROXIDE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; LYMPHOTOXIN; NEUROLEPTIC AGENT; PHORBOL ESTER; PHYTOHEMAGGLUTININ; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; TRANSFORMING GROWTH FACTOR BETA;

ADULT; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; INFLAMMATION; LEUKOCYTE; MALE; MONOCYTE; NEUTROPHIL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; SCHIZOPHRENIA; T LYMPHOCYTE;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CHLORPROMAZINE; CLOZAPINE; CYTOKINES; FEMALE; HALOPERIDOL; HUMANS; LEUKOCYTES; LIPOPOLYSACCHARIDES; MALE; NEUTROPHILS; PHORBOL ESTERS; PHYTOHEMAGGLUTININS; REACTIVE OXYGEN SPECIES; SUPEROXIDES;

EID: 4844231586     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Allen P. D., Bustin S. A., Macey M. G., Johnston D. H., Williams N. S. and Newland A. C. (1993): Programmed cell death (apoptosis) in immunity and haematological neoplasia. Br. J. Biomed. Sci., 50, 135-149.
2. Arolt V., Rothermundt M., Wandinger K.-P. and Kirchner H. (2000): Decreased in vitro production of interferon-γ and interleukin-2 in whole blood of patients with schizophrenia during treatment. Mol. Psychiatry, 5, 150-158.
3. Bertini R., Wang J. M., Mengozzi M., Willems J., Joniau M., Van Damme J. and Ghezzi P. (1991): Effect of chlorpromazine on PMN-mediated activities in vivo and in vitro. Immunology, 72, 138-143.
4. Boukhris W., Kouassi E. and Revillard J.P. (1988): Differential effect of mixed D1/D2 and selective D2 dopaminergic antagonists on mouse T and B lymphocyte proliferation and interleukin production in vitro. Immunopharmacol. Immunotoxicol., 10, 501-512.
5. Clancy K. D., Lorenz K., Dries D., Gamelli R. L. and Hahn E. L. (2000): Chlorpromazine modulates cytokine expression in the liver and lung after burn injury and endotoxemia. J. Trauma, 48, 215-222.
6. Fickenscher H., Hör S., Küpers H., Knappe A., Wittmann S. and Sticht H. (2002): The interleukin-10 family cytokines. Trends Immunol., 23, 89-96.
7. First M. (1997): SCID-I-structured clinical interview for DSM-IV axis I disorders. Clinician version. User's guide. Administration Booklet. American Psychiatric Press, Washington, DC.
8. Freed W. J. (1988): The therapeutic latency of neuroleptic drugs and non-specific postjunctional supersensitivity. Schizophr. Bull., 14, 269-277.
9. Hinze-Selch D., Becker E. W., Stein G. M., Berg P. A., Mullington J., Holsboer F. and Pollmächer T. (1998): Effect of clozapine on in vitro immune parameters: a longitudinal study in clozapine-treated schizophrenic patients. Neuropsychopharmacology, 19, 114-122.
10. Hinze-Selch D., Deuschle M., Weber B., Heuser I. and Pollmächer T. (2000): Effect of coadministration of clozapine and fluvoxamine versus clozapine monotherapy on blood cell counts, plasma levels of cytokines and body weight. Psychopharmacology, 149, 163-169.
11. Hinze-Selch D. and Pollmächer T. (2001): In vitro cytokine secretion in individuals with schizophrenia: results, confounding factors, and implications for further research. Brain Behav. Immun., 15, 282-318.
12. Jeding I., Evans P. J., Akanmu D., Dexter D., Spencer J. D., Aruoma O. I., Jenner P. and Halliwell B. (1995): Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biol. Pharmacol., 9, 359-365.
13. Joffe G., Nyberg P., Gross A. and Appelberg B. (1999): Clozapine-induced decrease in the production of reactive oxygen metabolites by monocytes in vitro may predict clinical response to clozapine in treatment-resistant schizophrenia. Hum. Psychopharmacol., 14, 203-209.
14. Kamińska T., Wysocka A., Marmurowska-Michałowska H., Dubas-Ślemp H. and Kandefer-Szerszeń M. (2001): Investigation of serum cytokine levels and cytokine production in whole blood cultures of paranoid schizophrenic patients. Arch. Immunol. Exp. Ther., 49, 439-445.
15. Katila H., Appelberg B., Hurme M. and Rimon R. (1994): Plasma levels of interleukin-1β and interleukin-6 in schizophrenia, other psychoses, and affective disorders. Schizophr. Res., 12, 29-34.
16. Kim Y.K., Suh I.B., Kim H., Han C.S., Lim C.S., Choi S.H. and Licinio J. (2002): The plasma levels of interleukin-12 in schizophrenia, major depression, and bipolar mania: effects of psychotropic drugs. Mol. Psychiatry, 7, 1107-1114.
17. Kowalski J., Blada P., Kucia K., Madej A. and Herman Z. S. (2001): Neuroleptics normalize increased release of interleukin-1β and tumor necrosis factor-α from monocytes in schizophrenia. Schizophr. Res., 20, 169-175.
18. Lane H. Y., Chang Y. C., Chang W. H., Lin S. K., Tseng Y. T. and Jann M. W. (1999): Effect of gender and age on plasma levels of clozapine and its metabolites: analysed by critical statistics. J. Clin. Psychiatry, 60, 36-40.
19. Lane H. Y., Lin H. N., Hwu H. G., Jann M., Hu W. H. and Chang W. H. (1995): Haloperidol plasma concentrations in Taiwanese psychiatric patients. J. Formosan Med. Assoc., 94, 671-678.
20. Leykin I., Mayer R. and Shinitzky M. (1997): Short and long-term immunosuppressive effects of clozapine and haloperidol. Immunopharmacology, 37, 75-86.
21. Lohr K. M., Feix J. B. and Kurth C. (1984): Chlorpromazine inhibits neutrophil chemotaxis beyond the chemotactic receptor-ligand interaction. J. Infect. Dis., 150, 643-652.
22. Maes M., Bosmans E., Calabrese J., Smith R. and Meltzer H. Y. (1995): Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatric Res., 29, 141-152.
23. Maes M., Bosmans E., Kenis E., DeJong R., Smith R. S. and Meltzer H. Y. (1997): In vivo immunoregulatory effects of clozapine in schizophrenia. Schizophr. Res., 26, 221-225.
24. Mahadik S. P. and Mukherjee S. (1996): Free radical pathology and antioxidant defence in schizophrenia: a review. Schizophr. Res., 19, 1-17.
25. Mangozzi M., Fantuzzi G., Faggioni R., Marchant A., Goldman M., Orencole S., Clark B. D., Sironi M., Benigni F. and Ghezzi P. (1994): Chlorpromazine specifically inhibits peritoneal and brain TNF production and up-regulates IL-10 production, in mice. Immunology, 82, 207-210.
26. Mayo L. A. and Curnutte J. T. (1990): Kinetic microplate assay for superoxide production by neutrophils and other phagocytic cells. Methods Enzymol., 86, 571-575.
27. Meltzer H. Y. (1995): Atypical antipsychotic drugs. In Bloom F. E. and Kupfer D. J. (eds.): Psychopharmacology, the Fourth Generation of Progress. Raven Press, New York, 1277-1286.
28. Meltzer H. Y. (1992): The mechanism of action of clozapine in relation to its clinical advantages. In Meltzer H. Y. (ed.): Novel Antipsychotic Drugs. Raven Press, New York, 1-13.
29. Monteleone P., Fabrazzo M., Tortorella A. and Maj M. (1997): Plasma levels of interleukin-6 and tumor necrosis factor alpha in chronic schizophrenia: effect of clozapine treatment. Psychiatry Res., 71, 11-17.
30. Moser M. (2001): Regulation of Th1/Th2 development by antigen presenting cells in vivo. Immunobiology, 204, 551-557.
31. Mukherjee S., Mahadik S. P., Scheffer R., Correnti E. E. and Kelhar H. (1996): Impaired antioxidant defence at the onset of psychosis. Schizophr. Res., 19, 19-26.
32. Müller N., Riedel M., Ackenheil M. and Schwarz J. (1999): The role of immune function in schizophrenia: an overview. Eur. Arch. Psychiatry Clin. Neurosci., 249 (suppl. 4), 62-68.
33. Pick E. (1986): Microassays for superoxide and hydrogen peroxide production and nitroblue tetrazolium reduction using an enzyme immunoassay microplate reader. Methods Enzymol., 132, 414-419.
34. Polimächer T., Hinze-Selch D. and Mullington J. (1996): Effects of clozapine on plasma cytokine and soluble cytokine receptor levels. J. Clin. Psychopharmacol., 16, 403-409.
35. Reddy R. D. and Yao J. K. (1996): Free radical pathology in schizophrenia: a review. Prostaglandins. Leukot. Essent. Fatty Acids, 55, 33-43.
36. Rudolf S., Peters M., Rothermund M., Arolt V. and Kirchner H. (2002): The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-γ in vitro. Neuropsychobiology, 46, 180-185.
37. Schleuning M. J., Duggan A. and Reem G. H. (1989): Inhibition by chlorpromazine of lymphokine-specific mRNA expression in human thymocytes. Eur. J. Immunol., 19, 1491-1495.
38. Song C., Lin A.H., Kenis G., Bosmans E. and Maes M. (2000): Immunosuppressive effects of clozapine and haloperidol: enhanced production of interleukin-1 receptor antagonist. Schizophr. Res., 42, 157-164.
39. Tanaka K. F., Shintani F., Fujii Y., Yagi G. and Asai M. (2000): Serum interleukin-18 levels are elevated in schizophrenia. Psychiatry Res., 96, 75-80.
40. Taniguchi K., Urakami M. and Tanaka K. (1988): Effect of various drugs on superoxide generation, arachidonic acid release and phospholipase A2 in polymorphonuclear leukocytes. Jpn. J. Pharmacol., 46, 275-284.
41. Tarazona R., Gonzales-Garcia A., Zamzami N., Marchetti P., Frechin N., Gonzalo J.A., Ruiz-Gayo M., van Rooijen N., Martinez C. and Kroemer G. (1995): Chlorpromazine amplifies macrophage-dependent IL-10 production in vitro. J. Immunol., 154, 861-870.
42. Traykov T., Hadjimitova V., Goliysky P. and Ribarov S. (1997): Effect of phenothiazines on activated macrophage-induced luminol-dependent chemiluminescence. Gen. Physiol. Biophys., 16, 3-14.
43. Yao J. K., Reddy R., McElhinny L. G. and van Kammen D. P. (1998): Effect of haloperidol on antioxidant defence system enzymes in schizophrenia. J. Psychiatric Res., 32, 385-391.
44. Yao J. K., Reedy R., McElhinny L. G. and van Kammen D. P. (1998): Reduced status of plasma antioxidant capacity in schizophrenia. Schizophr. Res., 32, 1-8.
45. Yaqoob P., Newsholme E. A. and Calder P. C. (1999): Comparison of cytokine production in cultures of whole blood and purified mononuclear cells. Cytokine, 8, 600-605.